EMERYVILLE, Calif., April 7,
2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL),
the functional cell biology company, today announced its
participation at the American Association of Cancer Research (AACR)
Annual Meeting 2023 being held from April
14-19 at the Orange County
Convention Center in Orlando, Fla.
AACR brings together scientists, clinicians, other health care
professionals, survivors, patients, and advocates to share the
latest advances in cancer science and medicine through this year's
meeting theme of "Advancing the Frontiers of Cancer Science and
Medicine."
At the conference, PhenomeX, the new company recently formed
through the combination of Isoplexis and Berkeley Lights, will
showcase its IsoSpark and Beacon® optofluidic platform technologies
and workflows in booth #3444. Attendees will have a chance to
explore demonstrations of the technologies and learn more about how
PhenomeX's applications can provide unparalleled insights into cell
function along the continuum of scientific discovery,
bioprocessing, translational, and clinical research.
In addition, the AACR Annual Meeting covers the latest advances
in cancer through a variety of poster and speaker presentations.
This year, PhenomeX technologies are highlighted in nine poster
presentations ranging from Polyfunctional Profiles and Cytokine
Secretion Activity of Transgenic TCR-T cells and Anti-Cancer
Macrophage-Based Cell Therapy to the Identification of
Myeloma-Specific T Cell Receptors by Functional Single Cell
Interaction Analyses. Some of the presenting abstracts
include:
- Dr. Scott Nowicki (UCLA) Abstract | Section 37 / 914/29
- Dr. Alejandro Villagra
(Georgetown) Abstract |
Section 37 – 900/15
- Dr. Wafik El-Deiry
(Brown) Abstract | Section 6 – 2518/26
- Dr. Alejandro Villagra
(Georgetown) Abstract |
Section 21 – 2880/18
- UT MD Anderson Abstract | Section 22 | 2903/8
- University of Wisconsin,
Madison Abstract | Section 25 – 4142/4
- National Institutions of Health (NIH) Abstract |
Section 23 – 4103/22
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional cell biology that
will advance human health. We enable scientists to reveal the most
complete insights on cell function and obtain a full view of the
behavior of each cell. Our unique suite of proven high-throughput
tools and services offer unparalleled resolution and speed,
accelerating the insights that are key to advancing discoveries
that can profoundly improve the prevention and treatment of
disease. Our award-winning platforms are used by researchers across
the globe, including those at the top 15 global pharmaceutical
companies and approximately 85% of leading U.S. comprehensive
cancer centers.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding PhenomeX or its
products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
PhenomeX undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-to-participate-in-american-association-of-cancer-research-annual-meeting-2023-301792302.html
SOURCE PhenomeX